1 – 10 of 91
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Delays in dealing with complaints against drug companies are growing, BMJ finds
(
- Contribution to specialist publication or newspaper › Specialist publication article
-
Mark
Evaluating time to withdrawal of anti-cancer drug indications that received FDA's accelerated approval
2024) In QJM - Monthly Journal of the Association of Physicians(
- Contribution to journal › Letter
-
Mark
Patterns of company misconduct, recidivism, and complaint resolution delays : A temporal analysis of UK pharmaceutical industry self-regulation within the European context
2024) In Regulation and Governance(
- Contribution to journal › Article
-
Mark
Broken beyond repair: self regulation of industry payments to clinicians and hospitals
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Continued cancer drug approvals in Japan and Europe after market withdrawal in the United States : A comparative study of accelerated approvals
(
- Contribution to journal › Article
-
Mark
Payments to healthcare organisations reported by the medical device industry in Europe from 2017 to 2019 : An observational study
(
- Contribution to journal › Article
- 2023
-
Mark
International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency
(
- Contribution to journal › Article
-
Mark
Short-circuiting biology: Digital phenotypes, digital biomarkers, and shifting gazes in psychiatry
2023) In Big Data and Society(
- Contribution to journal › Article
-
Mark
Race in clinical trials in Sweden: how regulatory and medical standards in clinical research trump the post-racial discourse
2023) In Sociology of Health & Illness(
- Contribution to journal › Article
-
Mark
Unethical pharmaceutical marketing: a common problem requiring collective responsibility
(
- Contribution to journal › Article